Pathobiochemistry of the extrapyramidal system: a “short note” review

@inproceedings{Riederer1989PathobiochemistryOT,
  title={Pathobiochemistry of the extrapyramidal system: a “short note” review},
  author={P. Riederer and E. Sofi{\'c} and W. Rausch and G. Hebenstreit and J. Bruinvels},
  year={1989}
}
  • P. Riederer, E. Sofić, +2 authors J. Bruinvels
  • Published 1989
  • Medicine
  • Evidence is presented to show that in Parkinson’s disease (PD) there exists a topographical degeneration in the nigrostriatal dopamine system. This finding may account for response variabilities and side effects occuring after antiparkinsonian therapy. Postsynaptic receptors do not show topical differences in both Bmax- and KD-values in treated PD. Postsynaptic receptors respond inadequately in about 30% of PD. Denervation supersensitivity may only occur in striatal subareas depleted of… CONTINUE READING
    9 Citations
    Neurotransmitters, neuroreceptors and aging
    • 95
    Dopaminergic dysfunction in alcoholism and schizophrenia--psychopathological and behavioral correlates.
    • A. Heinz
    • Psychology, Medicine
    • European psychiatry : the journal of the Association of European Psychiatrists
    • 2002
    • 223
    Sustained-release of levodopa: single dose study of a new formulation
    • 3

    References

    SHOWING 1-10 OF 19 REFERENCES
    The neurochemistry of Parkinson's disease: effect of L-dopa therapy.
    • 391
    Excretion of Dopamine in Diseases of Basal Ganglia
    • 194
    Transition Metals, Ferritin, Glutathione, and Ascorbic Acid in Parkinsonian Brains
    • 1,306
    Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases.
    • P. Seeman, N. Bzowej, +6 authors W. Tourtellotte
    • Chemistry, Medicine
    • Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
    • 1987
    • 309